Objective:To evaluate the efficacy of Gexia Zhuyu Decoction in the treatment of nonalcoholic fatty liver disease(NAFLD).Methods:Four Chinese databases(CNKI,CMB,Wanfang,VIP)and four English databases(PubMed,Embase,Coch...Objective:To evaluate the efficacy of Gexia Zhuyu Decoction in the treatment of nonalcoholic fatty liver disease(NAFLD).Methods:Four Chinese databases(CNKI,CMB,Wanfang,VIP)and four English databases(PubMed,Embase,Cochrane Library,Medline)were searched to screen randomized controlled trials(RCTs)of Gexia Zhuyu Decoction in the treatment of NAFLD.The enrollment of RCTs is from the starting date of database establishment till November 2,2022.and clinical registration tests and grey literatures were also searched.RCTs screening and relevant data exreacting were based on preset criteria.RevMan5.4.1 software was used for risk of bias assessment and Meta analysis of the included studies.Results:Eleven RCTs were included finally having 963 patients with NAFLD,including 499 in experimental group and 494 in control group.Meta-analysis results showed that GexiaZhuyu Decoction alone or combining with other medications for the treatment of NFALD was superior to that in control group in terms of total effective rate[RR=1.23,95%CI[1.16,1.31],Z=6.58(P<0.05)].Improve liver function index significantly:ALT[subgroup①WMD=-14.93,95%CI[-18.66,-9.42],Z=7.84(P<0.01);subgroup②WMD=-3.97,95%CI[-8.01,0.07],AST[subgroup①WMD=-13.25,95%CI[-18.10,-8.41],Z=5.36(P<0.05);subgroup②WMD=-2.70,95%CI[-6.94,1.54],Z=1.25(P>0.05)];GGT[WMD=-9.30,95%CI[-15.78,-2.81],Z=2.81(P<0.05)].Moreover,patients with therapy obviously decreased hepatic fibrosis index:桇-C[SMD=-1.15,95CI%[-1.48,-0.81],Z=6.77(P<0.05)],LN[SMD=-1.49,95CI%[-2.23,-0.75],Z=3.97(P<0.05)].Effectively reduce the level of LDL-C[WMD=-0.30,95CI%[-0.54,-0.06],Z=2.48(P<0.05)]and improve the rate of ultrasound renormalization[RR=1.94,95%CI[1.45,2.60],Z=4.48(P<0.05)].However,existing data cannot prove that the effect of reducing TC,TG and BMI in the treatment group is better than that in the control group:TC[WMD=-0.88,95CI%[-1.88,0.11],Z=1.74(P>0.05)],TG[WMD=-0.50,95CI%[-1.05,0.06],Z=1.76(P>0.05)],BMI[WMD=-1.61,95CI%[-4.77,1.54],Z=1.00(P>0.05)].Descriptive analysis results showed that the level展开更多
Objective:To analyse the key compounds,targets and pathways of the treatment of non‑alcoholic fatty liver disease(NAFLD)by Jianwei Gexia Zhuyu Decoction based on network pharmacology,in order to explore the molecular ...Objective:To analyse the key compounds,targets and pathways of the treatment of non‑alcoholic fatty liver disease(NAFLD)by Jianwei Gexia Zhuyu Decoction based on network pharmacology,in order to explore the molecular mechanism of its therapeutic effects.Methods:The differential genes between sick and normal conditions were screened by GEO‑Datasets,and the heat map and volcano map were drawn.The active compounds in Jianwei Gexia Zhuyu Decoction were searched by TCMSP platform and Drugbank database.OB≥30%and DL≥0.18 were set as thresholds to screen potential active compounds and action targets.The molecular target maps of Jianwei Gexia Zhuyu Decoction and NAFLD differential genes were constructed,and the PPI network and network topology parameters were obtained by STRING database.The PPI network and network topology parameters were visually analyzed by Cytoscape,and the core regulatory genes were screened.At the same time,the SwissDock platform was used to dock the main active components with the target.The main pathways were determined by GO biological function enrichment analysis and KEGG metabolic pathway enrichment analysis by DAVID.Results:After screening,377 differential genes(127 up‑regulated genes and 250 down‑regulated genes),225 active compounds of Jianwei Gexia Zhuyu Decoction,308 corresponding targets were obtained;14 key targets were screened,corresponding to 168 compounds,and the key targets involved MYC,FOSL2,FOS,etc.The results of GO functional enrichment analysis showed that Jianwei Gexia Zhuyu Decoction mainly regulated the activity expression of DNA binding transcriptional activator and the specific transcription of RNA polymeraseⅡ;The results of molecular docking showed that the main active components quercetin and baicalein had good binding activity with VCAM1,HSPB1,MYC,JUN and so on;The results of KEGG enrichment analysis showed that it was mainly involved in IL‑17 signal pathway,Wnt receptor signal pathway,NF‑κB signal pathway,TNF signal pathway and AGE‑RAGE signal pathwa展开更多
目的研究二甲双胍联合膈下逐瘀汤对经脱氢表雄酮诱导的多囊卵巢综合征(PCOS)模型大鼠外周血清炎性因子、性激素水平及糖脂代谢的影响。方法将69只PCOS(经脱氢表雄酮诱导)大鼠随机分为对照组(34只)和干预组(35只)。对照组大鼠每天给予二...目的研究二甲双胍联合膈下逐瘀汤对经脱氢表雄酮诱导的多囊卵巢综合征(PCOS)模型大鼠外周血清炎性因子、性激素水平及糖脂代谢的影响。方法将69只PCOS(经脱氢表雄酮诱导)大鼠随机分为对照组(34只)和干预组(35只)。对照组大鼠每天给予二甲双胍(270 mg/kg)灌胃,干预组大鼠每天给予二甲双胍(270 mg/kg)+膈下逐瘀汤(34.5 mg/kg)灌胃,连续治疗28 d。干预结束后,用ELISA法测定2组大鼠外周血清炎性因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)]、血脂[甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)]、血糖[空腹血糖(FPG)、餐后2 h血糖(2 h PG)]、激素水平[卵泡雌激素(FSH)、黄体生成素(LH)、雌激素(E_2)、睾酮(T)];用免疫组化法测定卵巢组织中IL-6、TNF-α蛋白表达。结果干预后2组大鼠外周血清IL-6、TNF-α、CRP、LH、LH/FSH、E_2、T、TG、LDL-C、TC、FPG、2 h PG均较治疗前有所降低(P<0.05),且干预组低于对照组(P<0.05);治疗后2组大鼠外周血清HDL-C、FSH较治疗前有所升高(P<0.05),且干预组高于对照组(P<0.05);干预后干预组大鼠的IL-6、TNF-α蛋白表达低于对照组(P<0.05)。结论二甲双胍联合膈下逐瘀汤能降低PCOS大鼠外周血清炎性因子浓度,并能改善循环中血脂、血糖水平及其激素水平,且效果优于单纯使用二甲双胍。展开更多
基金National Natural Science Foundation of China(No.81603418)Outstanding Young Talents Project of Heilongjiang Province(No.2020YQ05)。
文摘Objective:To evaluate the efficacy of Gexia Zhuyu Decoction in the treatment of nonalcoholic fatty liver disease(NAFLD).Methods:Four Chinese databases(CNKI,CMB,Wanfang,VIP)and four English databases(PubMed,Embase,Cochrane Library,Medline)were searched to screen randomized controlled trials(RCTs)of Gexia Zhuyu Decoction in the treatment of NAFLD.The enrollment of RCTs is from the starting date of database establishment till November 2,2022.and clinical registration tests and grey literatures were also searched.RCTs screening and relevant data exreacting were based on preset criteria.RevMan5.4.1 software was used for risk of bias assessment and Meta analysis of the included studies.Results:Eleven RCTs were included finally having 963 patients with NAFLD,including 499 in experimental group and 494 in control group.Meta-analysis results showed that GexiaZhuyu Decoction alone or combining with other medications for the treatment of NFALD was superior to that in control group in terms of total effective rate[RR=1.23,95%CI[1.16,1.31],Z=6.58(P<0.05)].Improve liver function index significantly:ALT[subgroup①WMD=-14.93,95%CI[-18.66,-9.42],Z=7.84(P<0.01);subgroup②WMD=-3.97,95%CI[-8.01,0.07],AST[subgroup①WMD=-13.25,95%CI[-18.10,-8.41],Z=5.36(P<0.05);subgroup②WMD=-2.70,95%CI[-6.94,1.54],Z=1.25(P>0.05)];GGT[WMD=-9.30,95%CI[-15.78,-2.81],Z=2.81(P<0.05)].Moreover,patients with therapy obviously decreased hepatic fibrosis index:桇-C[SMD=-1.15,95CI%[-1.48,-0.81],Z=6.77(P<0.05)],LN[SMD=-1.49,95CI%[-2.23,-0.75],Z=3.97(P<0.05)].Effectively reduce the level of LDL-C[WMD=-0.30,95CI%[-0.54,-0.06],Z=2.48(P<0.05)]and improve the rate of ultrasound renormalization[RR=1.94,95%CI[1.45,2.60],Z=4.48(P<0.05)].However,existing data cannot prove that the effect of reducing TC,TG and BMI in the treatment group is better than that in the control group:TC[WMD=-0.88,95CI%[-1.88,0.11],Z=1.74(P>0.05)],TG[WMD=-0.50,95CI%[-1.05,0.06],Z=1.76(P>0.05)],BMI[WMD=-1.61,95CI%[-4.77,1.54],Z=1.00(P>0.05)].Descriptive analysis results showed that the level
基金National Natural Science Foundation of China(NO.81603418)。
文摘Objective:To analyse the key compounds,targets and pathways of the treatment of non‑alcoholic fatty liver disease(NAFLD)by Jianwei Gexia Zhuyu Decoction based on network pharmacology,in order to explore the molecular mechanism of its therapeutic effects.Methods:The differential genes between sick and normal conditions were screened by GEO‑Datasets,and the heat map and volcano map were drawn.The active compounds in Jianwei Gexia Zhuyu Decoction were searched by TCMSP platform and Drugbank database.OB≥30%and DL≥0.18 were set as thresholds to screen potential active compounds and action targets.The molecular target maps of Jianwei Gexia Zhuyu Decoction and NAFLD differential genes were constructed,and the PPI network and network topology parameters were obtained by STRING database.The PPI network and network topology parameters were visually analyzed by Cytoscape,and the core regulatory genes were screened.At the same time,the SwissDock platform was used to dock the main active components with the target.The main pathways were determined by GO biological function enrichment analysis and KEGG metabolic pathway enrichment analysis by DAVID.Results:After screening,377 differential genes(127 up‑regulated genes and 250 down‑regulated genes),225 active compounds of Jianwei Gexia Zhuyu Decoction,308 corresponding targets were obtained;14 key targets were screened,corresponding to 168 compounds,and the key targets involved MYC,FOSL2,FOS,etc.The results of GO functional enrichment analysis showed that Jianwei Gexia Zhuyu Decoction mainly regulated the activity expression of DNA binding transcriptional activator and the specific transcription of RNA polymeraseⅡ;The results of molecular docking showed that the main active components quercetin and baicalein had good binding activity with VCAM1,HSPB1,MYC,JUN and so on;The results of KEGG enrichment analysis showed that it was mainly involved in IL‑17 signal pathway,Wnt receptor signal pathway,NF‑κB signal pathway,TNF signal pathway and AGE‑RAGE signal pathwa
文摘目的研究二甲双胍联合膈下逐瘀汤对经脱氢表雄酮诱导的多囊卵巢综合征(PCOS)模型大鼠外周血清炎性因子、性激素水平及糖脂代谢的影响。方法将69只PCOS(经脱氢表雄酮诱导)大鼠随机分为对照组(34只)和干预组(35只)。对照组大鼠每天给予二甲双胍(270 mg/kg)灌胃,干预组大鼠每天给予二甲双胍(270 mg/kg)+膈下逐瘀汤(34.5 mg/kg)灌胃,连续治疗28 d。干预结束后,用ELISA法测定2组大鼠外周血清炎性因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)]、血脂[甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)]、血糖[空腹血糖(FPG)、餐后2 h血糖(2 h PG)]、激素水平[卵泡雌激素(FSH)、黄体生成素(LH)、雌激素(E_2)、睾酮(T)];用免疫组化法测定卵巢组织中IL-6、TNF-α蛋白表达。结果干预后2组大鼠外周血清IL-6、TNF-α、CRP、LH、LH/FSH、E_2、T、TG、LDL-C、TC、FPG、2 h PG均较治疗前有所降低(P<0.05),且干预组低于对照组(P<0.05);治疗后2组大鼠外周血清HDL-C、FSH较治疗前有所升高(P<0.05),且干预组高于对照组(P<0.05);干预后干预组大鼠的IL-6、TNF-α蛋白表达低于对照组(P<0.05)。结论二甲双胍联合膈下逐瘀汤能降低PCOS大鼠外周血清炎性因子浓度,并能改善循环中血脂、血糖水平及其激素水平,且效果优于单纯使用二甲双胍。
